How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.  

Antibody Drug Conjugate
Debiopharm is interested in licensing Antibody Drug Conjugate drugs for cancer • Source: Shutterstock

More from Global Vision

More from In Vivo